Theranexus SA (FR:ALTHX) has released an update. Theranexus, in collaboration with the Beyond Batten Disease Foundation, reports positive 18-month results from its phase 1/2 study of Batten-1, ...
LYON, FRANCE and AUSTIN, TX / ACCESS Newswire / May 13, 2025 / Theranexus, a biopharmaceutical company developing drug candidates for rare neurological diseases, and the Beyond Batten Disease ...
THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug ...
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and ...
This press release updates an earlier issuance with updated language throughout. Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and ...
GENTILLY, France, February 10, 2026--(BUSINESS WIRE)--THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing ...
Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure Batten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results